Skip to main content
. 2018 Apr 20;9(30):21495–21511. doi: 10.18632/oncotarget.25138

Figure 9. Differential expression of p53 responsive pathway proteins (p21, Bcl2 and SOD2) in response to the treatment of PhiKan083 and SCH529074 in combination with Dox and TMZ (C: Control, P: PhiKan083-50 μM, S: SCH529074-1. 25 μM, D: Dox-1 μM, T: TMZ-100 μM, P+D: PhiKan083-50 μM and Dox-1 μM, P+T: PhiKan083-50 μM and TMZ-100 μM, S+D: SCH529074-1.25 μM and Dox-1 μM, S+T: SCH529074-1.25 μM and TMZ-100 μM).

Figure 9